Cure My Disease

Don't miss your cure!

 Log in / Sign up

New dosing strategy for myasthenia gravis drug shows promise

NCT ID NCT04980495

Completed Disease control Sponsor: argenx Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two different ways of giving the drug efgartigimod to people with generalized myasthenia gravis, a condition that causes muscle weakness. One group received the drug continuously, while the other got it in cycles. The goal was to see which schedule works better to control symptoms and improve daily activities. The study involved 69 adults and lasted up to 138 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

efgartigimod (a drug given by IV infusion)

What this could lead to

If successful, this study could help doctors find the best dosing schedule to control symptoms of generalized myasthenia gravis more effectively.

What could go wrong

This is a completed phase 3b study, but it is small (69 participants) and open-label, so results may not apply to all patients. The drug may still cause side effects or not work for everyone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENERALIZED MYASTHENIA GRAVIS GMG MG - MYASTHENIA GRAVIS

Contacts and locations

Locations

  • Investigator Site 1 - GEO9950001

    Tbilisi, 0114, Georgia

  • Investigator Site 10 - US0010007

    Carlsbad, California, 92011, United States

  • Investigator Site 11 - US0010011

    Austin, Texas, 78756, United States

  • Investigator Site 12 - US0010004

    Kansas City, Kansas, 66160, United States

  • Investigator Site 13 - US0010013

    Portland, Oregon, 97239, United States

  • Investigator Site 14 - US0010010

    Richmond, Virginia, 23219, United States

  • Investigator Site 15 - US0010014

    Coral Springs, Florida, 33067, United States

  • Investigator Site 16 - US0010009

    Augusta, Georgia, 30910, United States

  • Investigator Site 17 - US0010012

    Philadelphia, Pennsylvania, 19104, United States

  • Investigator Site 18 - ES0340002

    Santiago de Compostela, A Coruña, 15706, Spain

  • Investigator Site 19 - ES0340001

    Barcelona, 08041, Spain

  • Investigator Site 2 - GEO9950002

    Tbilisi, 0112, Georgia

  • Investigator Site 20 - FR0330001

    Marseille, 13385, France

  • Investigator Site 21 - IT0390002

    Milan, 20133, Italy

  • Investigator Site 22 - IT0390001

    Roma, 00168, Italy

  • Investigator Site 23 - FR0330005

    Bordeaux, 33604, France

  • Investigator Site 24 - FR0330004

    Lille, 59000, France

  • Investigator Site 25 - FR0330003

    Nice, 06001, France

  • Investigator Site 26 - AT0430002

    Innsbruck, 6020, Austria

  • Investigator Site 27 - AT0430001

    Vienna, 1090, Austria

  • Investigator Site 28 - BE0320001

    Leuven, 3000, Belgium

  • Investigator Site 29 - CA0019003

    London, N6A 5A5, Canada

  • Investigator Site 3 - GEO9950003

    Tbilisi, 0114, Georgia

  • Investigator Site 30 - IT0390004

    Genova, 16132, Italy

  • Investigator Site 31 - IT0390005

    Bologna, 40139, Italy

  • Investigator Site 32 - DE0490001

    Essen, 45147, Germany

  • Investigator Site 33 - DE0490004

    Berlin, 10117, Germany

  • Investigator Site 34 - DE0490005

    Hanover, 30625, Germany

  • Investigator Site 35 - NL0310001

    Amsterdam, 1105, Netherlands

  • Investigator Site 36 - DE0490002

    Bochum, 44791, Germany

  • Investigator Site 4 - PL0480001

    Lubin, 20-093, Poland

  • Investigator Site 5 - PL0480002

    Krakow, 31-426, Poland

  • Investigator Site 6 - US0010008

    Meadows, Illinois, 60008, United States

  • Investigator Site 7 - US0010001

    Orange, California, 92868, United States

  • Investigator Site 8 - US0010003

    Chicago, Illinois, 60611, United States

  • Investigator Site 9 - 0010006

    Boca Raton, Florida, 33487, United States

  • Investigator site 37 - CA0019002

    Québec, H3A 2B4, Canada

  • Investigator site 38 - FR0330002

    Paris, 75013, France

  • Investigator site 39 - IT0390006

    Pisa, 56126, Italy